Form 4: Director Michael Henderson Trades Spyre Therapeutics Stock

Director Michael Henderson reported a transaction involving 20,000 shares of Spyre Therapeutics, Inc. common stock on June 22, 2026, executed under a Rule 10b5-1 trading plan.

Summary

• Michael Thomas Henderson, a Director at Spyre Therapeutics, Inc. (SYRE), reported a transaction on June 22, 2026.
• The transaction involved the disposal of 20,000 shares of common stock.
• This transaction was executed as part of a pre-established Rule 10b5-1 trading plan adopted on February 6, 2026.
• Following this transaction, Henderson beneficially owns 68,606 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a director selling shares, the transaction was conducted under a pre-arranged Rule 10b5-1 plan, mitigating concerns about opportunistic insider trading.

Negatives

• Director Michael Henderson sold 20,000 shares of common stock.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it is a statement of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common for directors and executives to diversify holdings or manage personal finances in a pre-determined manner, aiming to avoid accusations of insider trading. The execution of such a plan by a director of Spyre Therapeutics indicates proactive financial planning by management.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director may be interpreted by some shareholders as a negative signal, although the Rule 10b5-1 plan context suggests it is a pre-planned financial action rather than a reflection of company performance.

Key Dates

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Rule 10b5-1, Stock Transaction, Director Trade